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Abstract
The aims of these studies were to establish an orthotopic non-small-cell lung cancer (NSCLC)
mouse model, and to investigate the therapeutic efficacy of lipid-based nanoparticles (NPs)
containing 2′-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) in this new model. A novel
orthotopic NSCLC model was established in nude mice through dorsal side injection of luciferase-
expressing A549 cells. The model was characterized by survival study, histological staining,
bioluminescence imaging and PET/CT imaging. The therapeutic efficacy of the Br-C16-DX NPs
versus Taxotere® was investigated in this model. The results demonstrated that mouse survival
time was significantly prolonged by weekly intravenous administration of the NPs or Taxotere.
Furthermore, the NPs group had 35 days longer progression-free survival and 27 days longer
median survival compared to the Taxotere group. It was concluded that the developed orthotopic
NSCLC model represents a feasible, reproducible, and clinically-relevant experimental mouse
model to test current and potential therapies including nanomedicines.
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Background
Lung cancer is the second most common cancer type and the leading cause of cancer
mortality worldwide. The estimated death caused by lung cancer in 2012 is 29% for males
and 26% for females in United States.1 Non-small cell lung cancer (NSCLC) including
squamous cell carcinoma, adenocarcinoma, and large cell carcinoma accounts for 85% of all
lung cancer cases.
The average five-year survival of NSCLC is only 15% with current therapies.1 Safer and
more effective treatment options are in great demand. A major hurdle of lung cancer
research for novel therapeutics has been lack of an easily feasible, reproducible, and
clinically-relevant experimental mouse model. Orthotopic models have the advantage over
ectopic models in that tumor grows in a microenvironment similar to clinical condition.
Lack of metastasis and altered drug responses have been reported in commonly used
subcutaneous tumors, which makes orthotopic models more favorable.2, 3 Reported methods
to establish orthotopic lung cancer mouse models with cell injection include injection
through the trachea or chest wall.4–7 However, a majority of the studies are still performed
in subcutaneous models due to lack of feasibility and reproducibility of previously reported
models.8 In this paper, we report our findings wherein we established and characterized a
bioluminescent orthotopic NSCLC model which provides high lung tumor development rate,
low surgery mortality, good heart protection, and reliable bioluminescence signal for long
term tumor growth monitoring.
Among the standard of care for NSCLC, docetaxel (DX) has been utilized either in
combination with platinum-based drug or as a single agent.9 Similar to other lipophilic
chemotherapy agents, its use has been limited by low water solubility, severe side-effects,
and drug resistance. Side effects of DX such as anemia, allergy and low white blood cell
count are partially caused by polysorbate 80 and ethanol in its commercialized form
Taxotere® (Sanofi-Aventis, Bridgewater NJ). Nanosystems including liposomes, micelles
and nanoparticles have been investigated as safer formulations for DX delivery, where the
use of polysorbate 80 and ethanol is avoided. Nanosystems provide advantages of decreased
toxicity, prolonged circulating time, enhanced permeation and retention (EPR) effect, and
potential targeted delivery.10–13 However, most DX formulations still face one or both
major limitations of moderate drug solubility and rapid drug release in vivo.
Previously, our group investigated the possibility to deliver DX with our lipid-based BTM
NPs (abbreviation from NP components Brij 78, Vitamin E TPGS and Miglyol 808).
Although DX has low water solubility, its solubility and affinity to the Miglyol oil core of
BTM NPs was not high enough, leading to relatively low drug entrapment of DX and rapid
drug release in vivo. To increase lipophilicity and subsequently drug entrapment and drug
retention, a series of lipid-ester conjugates of DX with different fatty-acid chain lengths (12,
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18, and 22) were successfully synthesized and incorporated into BTM NPs with significantly
higher entrapment efficiencies (50–60%).14 However, a common problem with taxane
derivatives is the compromised cytotoxicity due to sub-optimal hydrolysis kinetics of these
conjugates to release the parent drug. To overcome this limitation, a novel 2-Br-C16-DX
conjugate was synthesized in more recent studies, where the presence of a bromine (Br) at
the 2-position of the fatty acid chain leads to faster hydrolysis kinetics to release DX.15
Therapeutic efficacy of this system was investigated in the developed orthotopic NSCLC
model. The Br-C16-DX NPs had superior therapeutic efficacy over Taxotere, as evidenced
by the delayed tumor-relapse and prolonged overall survival.
Methods
Materials
D-luciferin potassium salt, Caliper IVIS Lumina II and Living Image software were from
Caliper (Hopkinton, Massachusetts). RPMI 1640, DPBS were purchased from Invitrogen
(Carlsbad, California). Matrigel was purchased from BD Biosciences (San Jose, California).
Primary antibodies for multidrug resistance-associated protein 1 (MRP1), lung resistance-
related protein (LRP) and p-glycoprotein (Pgp) were purchased from BIOSS (Woburn,
Massachusetts). Primary antibody for glutathione S-transferase π (GST-π) was purchased
from Millipore (Billerica, Massachusetts). Polyoxyl 20-stearyl ether (Brij 78) was purchased
from Uniqema (Wilmington, Delaware). D-alpha-tocopheryl polyethylene glycol-1000
succinate (Vitamin E-TPGS) was purchased from Eastman Chemicals (Kingsport,
Tennessee). Miglyol 808 was purchased from Sasol (Witten, Germany). Docetaxel Injection
Concentrate was purchased from Winthrop (Bridgewater, New Jersey).
Cell culture
Luciferase-expressing human lung adenocarcinoma cell line A549-luc-c8 (Caliper,
Hopkinton, Massachusetts) was maintained in RPMI 1640 supplemented with 10% FBS.
Cells were cultured in a humid incubator with 5% CO2 at 37 °C.
Orthotopic lung tumor implantation and survival study
Four to six week old female nude mice (Harlan Sprague Dawley) were housed in a
pathogen-free room. Mice were anesthetized with 100 mg/kg ketamine i.p., 1 mg/kg domitor
i.p., and topical 0.33% lidocaine hydrochloride. A 5 mm incision was made on dorsal side
over left lung, about 1.5 cm above the lower rib line. Fat and muscles were separated to
visualize lung movement. Luciferase expressing A549-luc-c8 cells suspended in 30 to 40 μl
PBS/matrigel were injected directly into left lung parenchyma at the depth of 3 mm. The
wound was closed with a surgery clip, which was removed 7 days later. After tumor cell
injection, 2.5 mg/kg Antisedan was administered subcutaneously for the reversal from
sedation. Mice were placed on a heating pad during and after the surgery procedure until
they recover from anesthesia. One million A549-luc-c8 cells were injected per mouse during
initial method development. However, in survival studies (n = 34), five million A549-luc-c8
cells were injected per mouse to achieve desirable survival time. All mouse studies were
conducted according to a protocol approved by the University of North Carolina
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Institutional Animal Care and Use Committee. Mice were sacrificed when Body Condition
Scoring was 2 or less, or at 20% weight loss.16
Whole-body bioluminescence imaging
Weekly whole-body bioluminescence imaging was performed in mouse studies to monitor
orthotopic lung tumor growth. D-luciferin potassium salt reconstituted in DPBS was injected
intraperitoneally at 150 mg/kg. Mice were anesthetized with 2% isoflurane and imaged by
Caliper IVIS Lumina II fifteen minutes after luciferin injection. The Region of Interest
(ROI) was defined as 3.2 cm radius circle over lung area. Total flux (photos/s) and average
radiance (p/s/cm2/sr) within ROI were quantified using Living Image.
Micro PET/CT imaging and correlation with bioluminescence imaging
Female nude mice were implanted with five million A549-luc-c8 cells per mouse as
described above (n=4). Tumor-bearing mice were first imaged in the in vivo
bioluminescence imaging system (IVIS-Kinetic, Perkin-Elmer, Inc.) using the protocol
described earlier. MicroPET imaging was then performed on the same day on those animals
using a small animal PET/CT scanner (eXplore Vista, GE Healthcare, Inc., Waukesha,
Wisconsin) with a center resolution of 1.2 mm. Animals were anesthetized by isofluorane
mixed with oxygen. [18]F-Fluorodeoxyglucose (FDG) with an average dose of 7.2 MBq
was injected through the tail vein catheter. A CT scan was first acquired for anatomical
localization and subsequent attenuation correction. PET acquisition was started at 30 min
after FDG injection and continued for 10 min. The optical and PET imaging was repeated on
the same animal every week for at least four weeks. Raw PET data were reconstructed using
2D ordered subset expectation maximization (OSEM) algorithms with scatter, random, and
attenuation correction using the manufacturer proprietary software. A standardized uptake
value (SUV) was calculated based on the injection dose and animal body weight. ROI was
manually drawn on the registered CT images along the rib cage to include the majority of
the lung but exclude heart tissue. Mean SUVs of the lung ROI at different time points were
reported, and compared to total flux (photos/s) of bioluminescence from the same mice.
Histology staining
At the time of sacrifice, various organs (lungs, heart, liver, spleen, kidney, brain) from the
mice were harvested and fixed in 10% formalin. After paraffin embedding, Hematoxylin &
Eosin (H&E) staining, Masson’s Trichrome staining, or immunohistochemistry staining
(MRP1, LRP, Pgp and GST-π) were performed for 4 μm sections by the Animal
Histopathology Core at UNC-Chapel Hill. Microscopic observations were carried out with
Olympus Bx-61 in Microscopy Services Laboratory at UNC-Chapel Hill.
Preparation and characterization of BTM NPs with Br-C16-DX
As previously reported, Br-C16-DX was synthesized from DX (Sigma-Aldrich, St. Louis,
Missouri) to enhance lipophilicity, drug entrapment and drug retention in BTM NPs.17, 18
Briefly, DX was conjugated with 2-bromohexadecanoic acid (Sigma-Aldrich, St. Louis,
Missouri) via a one-step esterification reaction. The product was purified by preparative
TLC, and confirmed by TLC, NMR, and mass spectrometry.18
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NPs with Br-C16-DX were prepared from a warm oil-in-water microemulsion precursor
developed and reported previously with Brij 78, Vitamin E TPGS and Miglyol 808, and
abbreviated as BTM NPs.19–21 Particle diameter and zeta potential of the NPs were
characterized as previously reported.14 Drug entrapment efficiency was determined by size
exclusion chromatography with Sepharose CL-4B, and the Br-C16-DX concentration was
quantified by HPLC.18
Efficacy study with Taxotere and Br-C16-DX NPs
Five million A549-luc-c8 cells were implanted by dorsal side injection on day 0 as described
above. Taxotere at 16 mg/kg or the Br-C16-DX NPs at 56 mg/kg of the conjugate
(established maximum tolerated dose, MTD) were injected through the tail vein starting on
day 5. Six weekly injections were performed on day 5, 12, 19, 26, 33 and 40. Weekly whole-
body bioluminescence imaging was performed from day 0 through the end of the study.
After mice were sacrificed, tissues were fixed in formalin for histological examination as
described above.
Statistical analysis
Student’s t-test was performed for two-group comparison, and Log-rank Test was performed
for survival comparison (Prism, Version 5.01, GraphPad Software Inc., La Jolla, CA, USA).
Differences were considered statistically significant when p < 0.05.
Results
Orthotopic lung tumor implantation and survival study
Luciferase-expressing A549-luc-c8 cells were used to establish orthotopic lung tumor model
since luminescence signal allowed for injection verification as well as semi-quantification of
tumor size and growth pattern. In vitro characterization proved a linear relationship between
quantified luminescence level and cell number (supplementary Figure S1, R2 0.9976), which
provided a basis for utilizing bioluminescence level to monitor in vivo tumor growth.
The tumor implantation procedure is shown in Figure 1A. After a mouse was anesthetized, a
5 mm incision was made on dorsal side over left lung. A549-luc-c8 cells suspended in
matrigel/PBS were injected into the left lung parenchyma to a depth around 3 mm and the
wound was closed with a skin clip. A survival study with 34 nude mice was carried out to
validate this tumor implantation method on a large animal set. With the dorsal side injection
technique, surgery mortality was 0% and lung tumor development rate was as high as 94%.
In studies investigating drug delivery system for cancer therapy, reasonable survival time in
the mouse model needs to be tuned and validated. In a study by Madero-Visbal et al., it was
reported that the median survival with one million A549 cells per mouse was around 60
days.22 In these current studies, we increased the number of cells injected to five million
cells per mouse, which resulted in a median survival of 32 days (Figure 1B). Quantified in
vivo bioluminescence increased in the beginning as tumor cells grew, then plateaued,
followed by a continuous increase until sacrifice. The “increase - decrease or plateau
continuous increase” pattern of bioluminescence level was observed repeatedly in all studies
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performed with this model. Lungs were harvested and gross images are shown in Figure 1C.
Unlike a healthy lung with smooth surface, tumor-bearing lungs showed the presence of
apparent disorganized tumor tissues. Pleural effusion was often observed in tumor-bearing
lungs at the time of sacrifice.
Histology characterization of the A549-luc-c8 tumor
H&E staining (Figure 2A–D) and Masson’s Trichrome staining (Figure 2E–H) were
performed in formalin-fixed tissues to further confirm tumor growth in the lung. Healthy
lungs were well organized with single-cell-layer alveoli, which provided large surface area
for air exchange and normal lung function. In contrast, tumor-bearing lungs presented
disrupted alveolar structure, and tumor cells with large, pale nuclei. Immune cell infiltration
and excess fibrin production in extracellular matrix were also observed in tumor-bearing
lungs, which further compromised lung function. In Masson’s Trichrome staining, a large
amount of blue collagen was seen in tumor-bearing lungs but not healthy lungs, reflecting
fibrosis during tumor growth.
The orthotopic lung tumor model was characterized for drug resistance due to its importance
in responses to chemotherapy. Several resistance-related proteins including MRP1, Pgp,
LRP and GST-π were stained by immunohistochemistry. MRP1 and Pgp are efflux
transporters of the ATP-binding cassette protein superfamily, which utilize energy from
ATP hydrolysis to transport toxins or drugs out of the cell. LRP is a membrane transporter
not belonging to the ATP-binding cassette superfamily. GST-π is a transferase involved in
drug detoxification pathway. As shown in Figure 2I–L, expressions of GST-π, MRP1 and
LRP, but not Pgp, were observed.
Micro PET/CT imaging
Micro PET/CT imaging was performed in addition to 2D optical bioluminescence imaging
(BLI) to obtain accurate 3D quantification in terms of tumor formation and metabolic
activity. As shown in Figure 3 upper panel, abnormal neoplasma in the lung was shown by
CT since day 21. Increasing FDG uptake signal in the lung was observed overtime (middle
panel), indicating higher glucose metabolic activities due to tumor growth. Lymph nodes
had high FDG uptake on day 41, implying metastasis of tumor cells. Weekly optical and
PET imaging was performed for more than four weeks and the quantified signals showed
increasing tumor burden overtime (Figure 3, lower panel). The relatively comparable signal
from day 7 to day 14 in BLI is likely attributable to limited tissue penetration of
bioluminescence signal and possible formation of a necrotic center in the tumor. Correlation
between FDG SUV in the lung from PET images and the bioluminescence photon level in
the lung from the same mouse was assessed (Figure 3, lower panel). A strong linear
correlation was observed for quantified SUV and bioluminescence levels from four different
mice over more than four weeks (R2 = 0.86). This correlation not only helped to validate the
orthotopic model but also supported the use of BLI to monitor tumor growth and therapeutic
response over time in the efficacy studies.
Peng et al. Page 6






















Preparation and chracterization of BTM NPs containing Br-C16-DX
Br-C16-DX (Figure 4) was synthesized as previously described and formulated in BTM
NPs.18 The long 16-carbon chain increases the solubility of the conjugate in the oil core of
the NPs, and the bromine (Br) atom at the 2-position of the fatty acid chain leads to faster
hydrolysis kinetics to release docetaxel. The Br-C16-DX NPs had a drug entrapment of 56.8
± 2.8%, mean particle diameter of 210 ± 2.15 nm, and zeta potential of −14.0 ± 0.9 mV in
0.05 molar phosphate buffer.18 In vitro release studies of Br-C16-DX NPs were performed
in 100% mouse plasma. An initial 40–45% burst release of Br-C16-DX was observed within
1 hour with little or no additional release over the next 8 hours.18
In vivo anti-tumor efficacy
The therapeutic efficacy of Br-C16-DX NPs was evaluated in the A549-luc-c8 orthotopic
lung tumor mouse model. Taxotere (16 mg/kg) or Br-C16-DX NPs (56 mg/kg of Br-C16-
DX) was administered intravenously at predetermined MTD starting day 5 post-tumor
implantation. The control group was left untreated (n = 9 in each group). Similar to the
survival study, the average bioluminescence in the control group increased in the beginning,
and then decreased, followed by a continuous increase (Figure 5A). BLI analysis showed
significantly lower luminescence levels in the Br-C16-DX NPs treatment group compared to
the control untreated group starting at day 13. The luminescence intensity in the Taxotere
group reached significantly lower levels compared to the untreated group one week later, at
day 20. Furthermore, the average luminescence level on day 20 in the NPs group was
significantly lower than that in the Taxotere group (1.25E+5 versus 4.70E+5 p/s/cm2/sr, p <
0.05).
Representative bioluminescence images for individual mouse are shown in Figure 5C–G.
For the majority of mice, luminescence signals were detected in a small region limited to left
lung on day 0 after tumor implantation. On day 5 when treatment was started, tumor cells
had spread to a larger area. On day 20, mice in the untreated group had developed very
strong luminescence signals, while mice in the Taxotere and NPs groups had significantly
lower luminescence levels, with the NP group exhibiting the lowest. The last treatment was
administered on day 40 in accordance with the clinical treatment regimen of six weekly i.v.
injections. Both the NPs and Taxotere groups showed baseline luminescence intensity levels
indicating very little tumor burden. With no further treatment, the Taxotere-treated group
was progression free until ~ day 70, after which tumors relapsed as indicated by an increase
in the luminescence intensity. In contrast, tumors in the NP-treated group relapsed only until
after day 105. Expression levels of MRP1, LRP, Pgp, GST-π of relapsed tumors in the two
treatment groups were quantified and compared to that of the original tumors in the
untreated group. Expression levels of MRP1, LRP and GST-π in relapsed tumors were all
significantly higher than that in untreated tumors (supplementary Figure S2), which could
indicate acquired drug resistance after treatment.
As shown in Figure 5B, the control group had a median survival of 41 days, which was
significantly improved by Taxotere treatment to 131 days. Survival by treatment with the
Br-C16-DX NPs was further enhanced to a median survival of 158 days. The improvements
were statistically significant compared to the control group (p<0.05 in Log-rank Test).
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Improved progression free survival and median survival in the NPs group suggest prolonged
systemic circulation and increased tumor accumulation of the Br-C16-DX NPs, as
demonstrated in previous pharmacokinetic studies.18 For both treatment groups, 55.6% of
the mice had been sacrificed at 158 days after tumor implantation. At this point, the study
was terminated as the remaining mice in each group had baseline levels of bioluminescence
intensity. Lungs from these surviving mice were harvested and fixed in formalin. Gross
images and H&E staining showed smooth surface and mostly normal lung histology with
organized alveoli (Figure 6). Metastasis was shown by positive luminescence in distant
tissues only in the control group with a rate of 11.1% (supplementary Figure S3).
Discussion
In these current studies, a clinically-relevant orthotopic NSCLC model was established in
nude mice. This model was shown to be feasible and reproducible using the dorsal side
injection technique, with 94% lung tumor development rate and 0% surgery mortality. The
Br-C16-DX NPs previously developed in our laboratory were investigated in this model and
shown to have superior therapeutic efficacy over commercial Taxotere.
At early stage of model development, we investigated an intrabronchial injection protocol
with a 1.2 cm needle reported by McLemore et al.4 After nasal luminescence was observed
following injection, the original method was refined by utilizing a one inch blunted needle
that was inserted deeper into trachea to allow the tumor cells to reach the lung instead of
resulting in nasal deposition due to normal breathing patterns of the mouse. However, this
method had surgery mortality of 13% during intrabronchial injection (n = 15). Furthermore,
with A549-luc-c8 cells implanted in the lung as confirmed by bioluminescence imaging,
lung tumor was successfully developed in only 47% of the mice three weeks post-injection.
Either luminescence signal in trachea or no luminescence was observed in 40% of the mice.
Tumor growth in upper airway is difficult to avoid with intrabronchial injection. Zou et al.
observed tumors in bronchus and neck despite careful withdrawal of the needle, and bathing
the wound in 70% ethanol after injection.5 Lung tumor was developed in only two out of
five mice in their studies.
Intrabronchial injection requires high level surgical skills and specialized devices such as a
surgical board and modified needles, which lead to lack of reproducibility of the injection
technique and compromised lung tumor development rate.23, 24 Mice needed to be
maintained in a reverse Trendelenburg maneuver using the McLemore protocol to keep
tumor cells in the distal airways of the right lung, which requires the use of surgical board
and full restraint of all limbs. Vertrees et al. held the mice in a head-up position, and utilized
a homemade endotracheal tube, a homemade laryngoscope, together with a piece of PE 50
tubing for cell injection.23 Kang et al. reported intrabronchial injection with a needle bent to
135° angle. The lung tumor development rate was only 20% even with A549 cells taken
from in vivo subcutaneous passaging in nude mice.24 However, the simultaneous
administration of EDTA improved the lung tumor development rate to 80% in their studies,
presumably due to slight disruption of the lung parenchymal epithelium and surfactant layer.
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Due to surgery complexity and unsatisfactory lung tumor growth, we later investigated
tumor injection directly through left chest wall. With an incision on the left chest, cell
suspensions were injected directly into the left lung parenchyma (n = 25). Subsequent
whole-body bioluminescence imaging revealed abdominal luminescence in 20% of the mice
likely due to heart puncture during injection (supplementary Figure S4). For some mice with
luminescence only in the lungs, positive luminescence was observed in the heart when
organs were imaged following autopsy. Lung tumor development rate by this direct chest
injection method was 72%.
To overcome above limitations, the surgical technique was modified wherein the cells were
injected from dorsal side over the left lung. Using this modification, the heart was better
protected from injection contamination since the injection site was further away
(supplementary Figure S4). Abdominal luminescence was observed occasionally but at
much lower rate. In a 65-mice study using this dorsal injection technique, abdominal
luminescence was observed in only two mice (3%). Chest cavities were imaged following
injection, and were proved to be clean (data not shown). Lung tumor development rate was
higher than 90% and surgery mortality was 0% in all studies with dorsal side injection.
Furthermore, model establishment was easily feasible and very reproducible. Mice could be
simply laid on their abdomen during injection with no need to restrain mice or to position
them with any special devices or equipment.
An “increase - decrease or plateau – continuous increase” pattern for in vivo
bioluminescence was observed repeatedly in the developed model with A549-luc-c8 cells.
Similar trend has been observed with intravenous injection of the same cell line into the
lungs of SCID mice.25 The decrease or plateau phase could be partially attributable to the
tissue attenuation of bioluminescence signal rising from the deep tissue, resulting in
unproportional increase of signal with the tumor growth. As shown in Figure 3 (lower
panel), day 7 and day 14 had increasing PET SUV but similar bioluminescence signal likely
due to tissue attenuation in BLI on day 14. It is notable that although there was a slight
deviation at lower signal range in the correlation between BLI and PET, a strong linear
correlation was observed overall (R2 = 0.86). Another potential cause of the plateau phase is
a necrotic formation typically in the center of the tumor due to insufficient nutrition supply.
In a study with subcutaneous A549 tumor, Ahmed et al. observed an increase in tumor
volume followed by a plateau around day 22 to day 25, and then continuous increase
afterwards.26 Since tumor volume is measured by geometrical dimensions in subcutaneous
model where tissue attenuation is not a concern, this plateau phase could be mainly caused
by the formation of a necrotic center in the tumor.
Orthotopic lung tumor growth and lymph node metastasis were shown by increased FDG
uptake in PET imaging. The mean SUV of the lung lesion reported here is slightly lower
compared to that in subcutaneous A549 model.27–29 This is mainly due to the different
approach in defining regions of interest in mean SUV measurement. ROI in subcutaneous
model only includes tumor tissue, while in our study, due to multiple tumor nodules and
small volume in earlier stage, the ROI was defined as the whole lung including tumor tissue
and healthy lung tissue, resulting in lower SUV in average. On the other hand, different
growth environment in orthotopic model could potentially play a role and lead to the
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different tumor metabolism level compared to the subcutaneous counterpart. Compared to
the results from the subcutaneous tumor model, the FDG PET imaging in the orthotopic
NSCLC model revealed more heterogeneity of FDG uptake, with SUV ranging from 0.5 to
7.3, and average SUV (max) of 4.07+/− 1.2. The PET imaging results in the orthotopic
model agree with the imaging pattern of human NSCLC with large heterogeneity and high
SUV (max) reported in the clinic. 30
The in vivo efficacy study showed that Br-C16-DX NPs provided a greater therapeutic
benefit than Taxotere in the A549-luc-c8 orthotopic lung tumor model. The NP-treated
group exhibited delayed tumor relapse from 70 to 105 days, and prolonged median survival
from 131 to 158 days as compared to the Taxotere group. These results suggest prolonged
systemic circulation and increased tumor accumulation of the Br-C16-DX NPs as was
previously established with this Br-C16-DX NP formulation in a subcutaneous breast cancer
model.18 For intravenously administered Taxotere or Br-C16-DX NPs at the same dose, the
plasma AUC0-∞ of NP-formulated Br-C16-DX was 100-fold higher than that of Taxotere,
and terminal half-life 8.7-fold higher. The DX AUC hydrolyzed from Br-C16-DX was
improved by 4.3-fold compared to Taxotere, and mean resonance time improved by 6.4-
fold. Furthermore, PK/biodistribution studies of BTM NPs with a drug conjugate were
performed in the developed orthotopic NSCLC model. The plasma half-life of the drug
conjugate from BTM NPs was prolonged to 7.9 hour compared to free drug at 0.8 hour,
producing a significantly higher dose-normalized AUC0–96h of 20405.5 (h*ng/ml)/(mg/kg)
for the NP-delivered conjugate compared to 878.0 (h*ng/ml)/(mg/kg) for the free drug. In
addition, the half-life of the drug conjugate in tumor-bearing lungs was 2.7-fold longer than
free drug (80.9 versus 30.3 hour) and the dose-normalized AUC0–96h was 12.6-fold greater
(34689.4 versus 2762.0 (h*ng/ml)/(mg/kg)). These results demonstrated that BTM NPs
significantly prolonged circulation time and increased drug exposure of the delivered drug to
the target tissue.
The linear correlation between BLI and PET (Figure 3, R2 = 0.86) in the orthotopic NSCLC
model supported the use of BLI to monitor tumor growth and to compare different treatment
groups and their response. BLI is also more time- and cost-effective than PET. In the
efficacy study, bioluminescence from A549-luc-c8 provided a reliable signal for tumor
growth up to more than 150 days. In the untreated group, both primary tumor growth and
late stage metastasis to lymph nodes were identified by positive bioluminescence signal. In
both treatment groups, suppression of original tumors, progression-free period, and tumor
relapse were shown by a decrease in luminescence to nearly baseline levels followed by an
increase in the luminescence upon tumor regrowth. Further, histological examination after
autopsy supported the imaging results.
Expression levels of drug resistance-related proteins were significantly higher in relapsed
tumors compared to untreated tumors. Nanomedicines have the potential to overcome drug
resistance through inhibition of drug efflux transporters, receptor-mediated endocytosis, or
unclear mechanisms.31–33 Specifically, BTM NPs have been previously proven to inhibit
Pgp and deplete ATP.34 Br -C16-DX NPs to treat resistant lung tumor could be further
investigated.
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Orthotopic lung tumor implantation and survival study. (A)Dorsal side lung tumor
implantation procedure. (B) Survival curve (left y-axis, circle) and whole-body
bioluminescence monitoring (right y-axis, triangle) in survival study (n=34). (C) Gross
images of tumor-bearing lungs with disorganized tumor tissue.
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Histology characterization of orthotopic lung tumors. (A–D) H&E staining of healthy lung
(A) and tumor-bearing lungs (B, C, D). (E–H)Masson’s Trichrome Staining of healthy lung
(E and F) and tumor-bearing lungs (G and H). (I–L) Immunohistochemistry for MRP1 (I),
LRP (J), GST-π (K) and Pgp (L). Scale bar, 120 μm.
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MicroPET/CT imaging and correlation with optial imaging. Upper panel, CT imaging of the
same mouse from day 7 to day 42. Middle panel, PET/CT overlay with an arrow in day 42
image indicating high FDG updake in lymph nodes. Lower panel, quantified signal from
bioluminescence imaging (BLI, left), FDG PET imaging (middle), and the correlation of
these two imaging approaches (right, R2 = 0.86).
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Efficacy study with Taxotere and Br-C16-DX NPs. (A) Quantified average luminescence
levels in different groups. Red asterisk, NPs group vs. control group on day 13, p < 0.05.
Blue asterisk, Taxotere group versus control group on day 20, p < 0.05. +, NPs group versus
Taxotere group on day 20, p < 0.05. (B) Survival curve. Tail vein injections are indicated by
the arrows. (C) and (D), Representative whole-body bioluminescence image on day 0 (C)
and day 5 (D). (E–G), representative bioluminescence images on day 20 in control (E),
Taxotere (F), and NP group (G).
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Gross images and H&E staining of lungs from surviving mice in two treatment groups.
Scale bar, 60 μm.
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